Blog
RSS FeedPosted by Michael Wonder on 06 Dec 2019
Proposed changes to research and development tax incentive will discourage investment and undermine innovation
6 December 2019 - Medicines Australia is disappointed that proposed changes to the Research and Development Tax Incentive were tabled ...
Posted by Michael Wonder on 17 Oct 2019
Pelosi’s drug pricing plan puts medical innovation at risk
17 October 2019 - The future of medical innovation in America is at a crossroads. ...
Posted by Michael Wonder on 26 Jul 2019
Intellectual property law amends will add to business uncertainty
26 July 2019 - Medicines Australia supports efforts to strengthen Australia’s Intellectual Property arrangements to be consistent with international best ...
Posted by Michael Wonder on 14 Jul 2019
How the FDA uses science to speed medical device innovation
11 July 2019 - The MDDT program streamlines the medical device development and review process. ...
Posted by Michael Wonder on 02 Jul 2019
Innovation prizes to support cell and gene therapy
2 July 2019 - Personalised cell and gene therapy represent a fundamental therapeutic revolution. ...
Posted by Michael Wonder on 20 Jun 2019
Sustainable discovery and development of antibiotics — is a non-profit approach the future?
19 June 2019 - Shifting to a nonprofit-driven model for development of antibiotics could encourage discovery and development of truly needed ...
Posted by Michael Wonder on 06 Feb 2019
FDA finalises new policy to encourage widespread innovation and development of new buprenorphine treatments for opioid use disorder
6 February 2019 - Today, the U.S. FDA issued a final guidance, “Opioid Use Disorder: Developing Buprenorphine Depot Products for Treatment,” ...
Posted by Michael Wonder on 24 Jan 2019
Toward an effective innovation agenda
23 January 2019 - Digital technologies have transformed the U.S. and global economies, offering tremendous benefits to consumers and financial success ...
Posted by Michael Wonder on 07 Jan 2019
2018: a year of innovation, efficiency, and new advances in drug therapy for the American public
7 January 2019 - The beginning of a new year is a good opportunity to look back over the past ...
Posted by Michael Wonder on 18 Dec 2018
Statement from FDA Commissioner and Director of the Center for Devices and Radiological Health on new steps to promote innovations in medical devices that help advance patient safety
18 December 2018 - Spurring innovation of medical products so that patients can have access to safe, effective treatments that ...
Posted by Michael Wonder on 06 Dec 2018
Why regulators must move with the science if we’re to get innovative new treatments to patients more quickly
5 December 2018 - Professor Paul Workman, discusses the findings of the ICR's new drug access report, which asks how we ...
Posted by Michael Wonder on 26 Sep 2018
The health industry as an economic priority for Victoria, joint statement
26 September 2018 - Victoria has world-leading competitive advantages in the health industry, which encompasses health and medical research, biotechnology, ...
Posted by Michael Wonder on 17 Sep 2018
Antimicrobial resistance: FDA discusses reimbursement reforms
17 September 2018 - Reimbursement reforms for antimicrobial treatments could include “a mix of milestone payments and subscription fees for ...
Posted by Michael Wonder on 30 Aug 2018
FDA’s comprehensive effort to advance new innovations: initiatives to modernise for innovation
29 August 2018 - Our longstanding goal for medical care is to ensure that the right drug or device is delivered ...
Posted by Michael Wonder on 29 Aug 2018
FDA launches new pilot to advance innovative clinical trial designs as part of agency’s broader program to modernise drug development and promote innovation in drugs targeted to unmet needs
29 August 2018 - Today, the U.S. FDA announced a new pilot program (“Complex Innovative Designs Pilot Meeting Program”) in which ...